Factors affecting prognosis and need for anti-vascular endothelial growth factor injections in wet age-related macular degeneration

Purpose: To understand factors affecting visual prognosis and the number of intravitreal antivascular endothelial growth factor (anti-VEGF) injections needed to stabilize wet age-related macular degeneration (AMD). Methods: In this retrospective cohort, 119 treatment-naïve wet AMD patients were followed for two years. In patients with bilateral disease, the eye with worse best-corrected visual acuity (BCVA) or that received more intravitreal injections was recruited as the study eye. In all visits, BCVA was recorded, ophthalmological examination was performed including macular optical coherence tomography imaging. Twenty health status / lifestyle questions were asked to the patients via phone as potential risk factors. All patients received 3 loading doses of intravitreal bevacizumab injections and received repeat injections of aflibercept or ranibizumab when the eye had a new, active neovascular lesion. Results: Patients who took regular micronutrition had similar visual outcome and injection numbers compared to the ones who did not. Patients with bilateral disease needed less intravitreal injections compared to unilateral AMD patients (p=0.016) and women on hormone replacement therapy (HRT) required less injections compared to the women who were not (p=0.024). Female patients had a mean gain of 2.7 letters while male patients lost 3.8 letters (p=0.038). Wet AMD started at an earlier age in smokers (p=0.002). Patients with a better education level presented earlier with better BCVA (p=0.037). Conclusion: HRT and anti-VEGF injections to the fellow eye improved the prognosis of wet AMD, while male patients had slightly worse prognosis. estrogen’s protective effects and potential contribution in wet AMD needs further attention. Retrospectively registered: 2020/0622